Covalon Technologies Ltd.’s head office is located at 1660 Tech Avenue, Unit 5, Mississauga, Ontario, Canada, L4W 5S7.
Covalon Technologies Ltd. is incorporated in Ontario, Canada.
Covalon Technologies Ltd. was founded in 1999 and subsequently went public in 2004.
Covalon Technologies Ltd.’s fiscal year ends September 30.
Covalon Technologies Ltd. is traded on the TSX Venture Exchange (symbol: COV) and OTCQX Markets (symbol: CVALF).
Covalon Technologies Ltd. does not pay a dividend at this time.
Covalon Technologies Ltd.’s transfer agent is TSX Trust.
For questions about your stock, please contact Brian Pedlar (bpedlar@covalon.com).
No, Covalon Technologies Ltd. does not have a direct stock purchase plan.
Covalon Technologies Ltd.’s auditor is PricewaterhouseCoopers LLP.
Covalon Technologies Ltd. is a researcher, developer, manufacturer, and marketer of patent-protected medical products that improve patient outcomes and save lives in the areas of advanced wound care, infection management and surgical procedures.
Covalon Technologies Ltd. leverages its patented medical technology platforms and expertise in two ways: (i) we develop products that we sell under Covalon’s name; and (ii) we develop and commercialize medical products for other medical companies under development and license contracts.
The majority of Covalon-branded products are sold through independent distributors to various health care providers such as hospitals, wound care centers, burn centers, extended/alternate care facilities, acute care facilities, home health care agencies, and physicians’ offices. Many of Covalon’s products require regulatory clearances and are sold on a prescription basis in the United States, Canada, the Middle East, Latin America, Asia, and a number of other international countries.
Covalon also licenses its technologies and products to large medical device companies and niche start-ups to create novel technology to advance our product offerings in various medical device markets. Covalon has worked with over twenty medical companies, including leaders in vascular access devices, I.V. infusion, orthopedics, device and patient care distributors, wound care product companies, specialty medical device manufacturers and major contract manufacturers.
Covalon Technologies Ltd. currently has three proprietary platform technologies that have the potential to be developed into dozens of medical devices: (i) Biological matrix; (ii) Antimicrobial silicone adhesive; and (iii) Medical Coating technology. These platform technologies are protected by patents, patent applications and patents pending, patented and proprietary manufacturing processes, trade secrets, brands, trademarks, and trade names.
Covalon Technologies Ltd.’s patented Biological Matrix platform is used to manufacture a family of products that treat chronic and infected wounds including diabetic ulcers (including diabetic foot ulcers), pressure ulcers, venous ulcers (including venous leg ulcers), donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns. These dressings begin from a biological collagen base, which is generally biocompatible with the human body, and enable the release of beneficial materials, such as antimicrobials, into the wound site and/or enhance the removal of undesirable materials, such as wound exudate from the wound. Covalon’s patented manufacturing process for creating our biological matrix results in products that have certain clinical advantages over other dressings, such as open binding sites for destructive enzymes, effective antimicrobial activity, and exudate management properties that help chronic wounds heal.
Covalon Technologies Ltd.’s patent-pending antimicrobial silicone adhesive platform is the basis for a family of pre-surgical, post-surgical and vascular access products that are designed to kill 99.99% or more of any bacteria or yeast that comes into contact with the antimicrobial silicone. The Company’s Antimicrobial Silicone Adhesive platform is unique because the silicone adhesive contains both silver and chlorhexidine which provides broad-spectrum antimicrobial activity for a minimum of 7 days, while maintaining the beneficial properties of a silicone adhesive. Our technology meets or exceeds the current United States Food and Drug Administration’s “greater than 4 log reduction” standard for an antimicrobial claim against bacteria, and yeast, most commonly associated with healthcare acquired infections. The soft silicone adhesive also provides greater patient comfort, does not macerate or damage the skin, and was shown to be up to 10 times less painful upon removal when compared to acrylic adhesives, which are commonly used in medical products containing adhesives.
A highly versatile coating, CovaCoat® is a photochemical process that enables permanent covalent attachment of the coating to a wide variety of medical devices. Each formulation is specifically tailored to the device, and can be engineered to improve lubricity, hemocompatibility, infection prevention and controlled delivery of active pharmaceutical ingredients (APIs).
You can learn more about Covalon Technologies Ltd. by visiting the corporate website www.covalon.com.
Please visit the email alerts page and fill out the web form to be added to the distribution list.
Quarterly and annual reports and other investor materials, when available, can be found on the Quarterly Results page. Additionally, all filings can be accessed directly from the website, www.sedar.com.
Please visit the corporate governance section to view Covalon Technologies Ltd.’s Executive Management Team and Board of Directors.
For more information about products please visit the Products section of Covalon Technologies Ltd.’s corporate website.
Covalon Technologies Ltd., reports financial results on a quarterly basis. For more information about financial releases and upcoming events please visit the “News and Events” page of “Investor Relations” section of our corporate website. Please visit the email alerts page and fill out the web form to be added to the distribution list.
A copy of the annual report and proxy are mailed out to shareholders of record on a yearly basis. The prior year’s annual report and proxy can be found in “Quarterly Results” in the “Financial Info” of the “Investor Relations” section of our corporate website. Additionally, all filings can be accessed directly from the website www.sedar.com.
You may contact Brian Pedlar (bpedlar@covalon.com) for investor inquiries.